pertuzumab
Selected indexed studies
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. (Lancet Oncol, 2020) [PMID:32171426]
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. (N Engl J Med, 2026) [PMID:41160818]
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. (N Engl J Med, 2017) [PMID:28581356]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. (2026) pubmed
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. (2020) pubmed
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. (2017) pubmed
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. (2012) pubmed
- Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. (2015) pubmed
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. (2021) pubmed
- Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. (2021) pubmed
- Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. (2018) pubmed
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. (2012) pubmed
- Pertuzumab for the treatment of breast cancer. (2020) pubmed